Petter Bjornstad, Silva A Arslanian, Tamara S Hannon, Philip S Zeitler, Jennie L Francis, Alexandra M Curtis, Ibrahim Turfanda, David A Cox
{"title":"Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study.","authors":"Petter Bjornstad, Silva A Arslanian, Tamara S Hannon, Philip S Zeitler, Jennie L Francis, Alexandra M Curtis, Ibrahim Turfanda, David A Cox","doi":"10.2337/dc24-0322","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo.</p><p><strong>Research design and methods: </strong>Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.</p><p><strong>Results: </strong>Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.8 vs. -0.1 mL/min/1.73 m2; P = 0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively).</p><p><strong>Conclusions: </strong>Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.</p>","PeriodicalId":93979,"journal":{"name":"Diabetes care","volume":" ","pages":"1617-1621"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/dc24-0322","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To examine changes in glomerular hyperfiltration and other measures of kidney function in youth with type 2 diabetes treated with dulaglutide or placebo.
Research design and methods: Post hoc analysis was performed on kidney laboratory data from 154 youths (age 10-18 years) with type 2 diabetes enrolled in a completed placebo-controlled glycemic control trial of dulaglutide.
Results: Mean estimated glomerular filtration rate (eGFR) decreased from baseline to 26 weeks in participants treated with dulaglutide versus placebo (-5.8 vs. -0.1 mL/min/1.73 m2; P = 0.016). Decreases in eGFR were observed primarily in participants with baseline glomerular hyperfiltration. At 26 weeks, the prevalence of both glomerular hyperfiltration and proteinuria increased with placebo but decreased with dulaglutide (P = 0.014 and 0.004 vs. placebo, respectively).
Conclusions: Dulaglutide was associated with attenuated glomerular hyperfiltration and proteinuria in youth with type 2 diabetes. The impact of these changes on the risk of diabetic kidney disease is unclear.
研究目的考察接受度拉鲁肽或安慰剂治疗的2型糖尿病青少年肾小球高滤过率和其他肾功能指标的变化：对154名2型糖尿病青少年（10-18岁）的肾脏实验室数据进行了事后分析，这些青少年参加了已完成的安慰剂对照的度拉鲁肽血糖控制试验：结果：与安慰剂相比，接受度拉鲁肽治疗的参与者从基线到26周的平均估计肾小球滤过率（eGFR）有所下降（-5.8 vs. -0.1 mL/min/1.73 m2; P = 0.016）。eGFR的下降主要出现在基线肾小球高滤过率患者中。在26周时，肾小球高滤过率和蛋白尿的发生率在服用安慰剂后有所上升，但在服用度拉鲁肽后有所下降（与安慰剂相比，P = 0.014和0.004）：结论：度拉鲁肽可减轻青少年2型糖尿病患者的肾小球高滤过率和蛋白尿。这些变化对糖尿病肾病风险的影响尚不清楚。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
